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An important goal of DNA microarray research is to develop tools to diagnose cancer more accurately based on the
genetic profile of a tumor. There are several existing techniques in the literature for performing this type of diagnosis.
Unfortunately, most of these techniques assume that different subtypes of cancer are already known to exist. Their
utility is limited when such subtypes have not been previously identified. Although methods for identifying such
subtypes exist, these methods do not work well for all datasets. It would be desirable to develop a procedure to find
such subtypes that is applicable in a wide variety of circumstances. Even if no information is known about possible
subtypes of a certain form of cancer, clinical information about the patients, such as their survival time, is often
available. In this study, we develop some procedures that utilize both the gene expression data and the clinical data to
identify subtypes of cancer and use this knowledge to diagnose future patients. These procedures were successfully
applied to several publicly available datasets. We present diagnostic procedures that accurately predict the survival of
future patients based on the gene expression profile and survival times of previous patients. This has the potential to
be a powerful tool for diagnosing and treating cancer.
Introduction
Predicting Patient Survival
When a patient is diagnosed with cancer, various clinical
parameters are used to assess the patient’s risk proﬁle.
However, patients with a similar prognosis frequently
respond very differently to the same treatment. This may
occur because two apparently similar tumors are actually
completely different diseases at the molecular level (Alizadeh
et al. 2000; Sorlie et al. 2001; van de Vijver et al. 2002; van’t
Veer et al. 2002; Bullinger et al. 2004; Lapointe et al. 2004).
The main example discussed in this paper concerns diffuse
large B-cell lymphoma (DLBCL). This is the most common
type of lymphoma in adults, and it can be treated by
chemotherapy in only approximately 40% of patients
(NHLCP 1997; Vose 1998; Coifﬁer 2001). Several recent
studies used DNA microarrays to study the gene expression
proﬁles of patients with DLBCL. They found that it is possible
to identify subgroups of patients with different survival rates
based on gene expression data (Alizadeh et al. 2000;
Rosenwald et al. 2002; Shipp et al. 2002).
If different subtypes of cancer are known to exist, there are
a variety of existing techniques that can be used to identify
which subtype is present in a given patient (Golub et al. 1999;
Hastie et al. 2001a; Hedenfalk et al. 2001; Khan et al. 2001;
Ramaswamy et al. 2001; Nguyen and Rocke 2002a, 2002b;
Shipp et al. 2002; Tibshirani et al. 2002; van de Vijver et al.
2002; van’t Veer et al. 2002; Nutt et al. 2003). However, most
of these techniques are only applicable when the tumor
subtypes are known in advance. The question of how to
identify such subtypes, however, is still largely unanswered.
There are two main approaches in the literature to identify
such subtypes. One approach uses unsupervised learning
techniques, such as hierarchical clustering, to identify patient
subgroups. This type of procedure is called ‘‘unsupervised’’
since it does not use any of the clinical information about the
patient. The subgroups are identiﬁed using only the gene
expression data. (In contrast, ‘‘supervised learning’’ would use
the clinical data to build the model.) For an overview of
unsupervised learning techniques, see Gordon (1999) or
Hastie et al. (2001b).
Hierarchical clustering (Eisen et al. 1998) has successfully
identiﬁed clinically relevant cancer subtypes in several
different studies (Alizadeh et al. 2000; Bhattacharjee et al.
2001; Sorlie et al. 2001; Beer et al. 2002; Lapointe et al. 2004).
However, one drawback to unsupervised learning procedures
is that they may identify cancer subtypes that are unrelated to
patient survival. Although several different subtypes of a
given cancer may exist, if the prognosis for all patients is the
same regardless of which subtype they have, then the utility of
this information is limited. Since unsupervised learning
procedures by deﬁnition do not use the clinical data to
identify subtypes, there is no guarantee that the subtypes they
identify will be correlated with the clinical outcome.
The second approach to identifying subtypes of cancer is
based exclusively on the clinical data. For example, patients
can be assigned to a ‘‘low-risk’’ or a ‘‘high-risk’’ subgroup
based on whether they were still alive or whether their tumor
had metastasized after a certain amount of time. This
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PLoS BIOLOGYapproach has also been used successfully to develop proce-
dures to diagnose patients (Shipp et al. 2002; van de Vijver et
al. 2002; van’t Veer et al. 2002).
However, by dividing the patients into subgroups based on
their survival times, the resulting subgroups may not be
biologically meaningful. Suppose, for example, that there are
two tumor cell types. Suppose further that patients with cell
type 2 live slightly longer than patients with cell type 1 but
that there is considerable overlap between the two groups
(Figure 1). Assume also that the underlying cell types of each
patient are unknown. If we were to assign patients to ‘‘low-
risk’’ and ‘‘high-risk’’ groups based on their survival times,
many patients would be assigned to the wrong group, and any
future predictions based on this model would be suspect. We
can obtain more accurate predictions by identifying these
underlying subtypes and building a model that can determine
which subtype is present in future patients.
Proposed Semi-Supervised Methods
To overcome these difﬁculties, we propose a novel
procedure that combines both the gene expression data and
the clinical data to identify cancer subtypes. The crux of the
idea is to use the clinical data to identify a list of genes that
correlate with the clinical variable of interest and then apply
unsupervised clustering techniques to this subset of the genes.
For instance, in many studies, the survival times of the
patients are known even though no tumor subtypes have been
identiﬁed (Alizadeh et al. 2000; Bhattacharjee et al. 2001;
Sorlie et al. 2001; Beer et al. 2002; Rosenwald et al. 2002;
Shipp et al. 2002; van de Vijver et al. 2002; van’t Veer et al.
2002; Nutt et al. 2003; Bullinger et al. 2004). We can calculate
the Cox score for each gene in the expression data—the Cox
score measures the correlation between the gene’s expression
level and patient survival—and consider only the genes with a
Cox score that exceeds a certain threshold.
Once such a list of signiﬁcant genes is compiled, there are
several methods we can use to identify clinical subgroups. We
can apply clustering techniques to identify subgroups of
patients with similar expression proﬁles. Once such sub-
groups are identiﬁed, we can apply existing supervised
learning techniques to classify future patients into the
appropriate subgroup. In this study, we will use the ‘‘nearest
shrunken centroids’’ procedure of Tibshirani et al. (2002),
which is implemented in the package PAM (Tibshirani et al.
2003). For a brief description of the procedure, see ‘‘Materials
and Methods.’’
Sometimes, however, a continuous predictor of survival is
desired. We also describe a supervised version of principal
components analysis that can be used to calculate a
continuous risk score for a given patient and identify
subtypes of cancer. The resulting predictor performs very
well when applied to several published datasets.
These two methods will produce satisfactory results in most
datasets. However, we will describe some variations of these
methods that can sometimes improve their performance.
When we cluster a dataset using only a subset of the genes, it
is important that we choose the correct subset of genes.
Choosing the genes with the largest Cox scores is generally a
good strategy, but this procedure sometimes selects some
spurious genes. We will show that one can use partial least
squares (PLS) to compute a ‘‘corrected’’ Cox score. Selecting
the genes with the largest ‘‘corrected’’ Cox scores can
produce better clusters than selecting genes with largest
raw Cox scores. Additionally, we will describe two other
continuous predictors of survival that we will call ~ b b and ^ c c. For
some problems, they are better predictors than the contin-
uous predictor based on supervised principal components
(Figures S1–S3). These methods are described in Pro-
tocol S1.
Related Methods in the Literature
Ben-Dor et al. (2001) and von Heydebreck et al. (2001)
attempt to identify biologically meaningful tumor subtypes
from gene expression data by clustering on a subset of the
genes. The important distinction between these methods and
our semi-supervised clustering method is that our method
uses the available clinical data to choose the subset of the
genes that is used to perform the clustering. The methods of
von Heydebreck et al. (2001) and Ben-Dor et al. (2001) do not
use this clinical information. We will show that utilizing the
available clinical data can improve the quality of the
clustering.
There are also related methods for predicting the survival
of cancer patients using gene expression data. Nguyen and
Rocke (2002a) use a form of PLS to predict survival. Li and
Luan (2003) use support vector machines (SVMs). However, a
drawback of these methods is the fact that they use a
combination of all of the genes to predict survival. Since the
vast majority of the genes in a given dataset are unrelated to
survival, the result is that many of the inputs to the model are
superﬂuous, which reduces the predictive accuracy of the
model. We will show that our semi-supervised methods, which
use only a subset of the genes, generally perform better than
these methods.
Moreover, in many applications, we would like to identify
which genes are the best predictors of survival. These genes
could be analyzed in the laboratory to attempt to discover
how they inﬂuence survival. They could also be used to
develop a diagnostic test based on immunostaining or reverse
transcriptase PCR. For these applications, it is important to
have a predictor of survival that is based on a small subset of
the genes. This is another important advantage of our
methods over existing methods.
Figure 1. Two Patient Subgroups with Overlapping Survival Times
DOI: 10.1371/journal.pbio.0020108.g001
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Methods to Predict Patient SurvivalBeer et al. (2002) utilized an ad hoc method that ﬁt a series
of univariate Cox proportional hazards models and took a
linear combination of the resulting coefﬁcients. A brief
description of their method is given in Protocol S1. This
method is similar to our methods in that it selects a relevant
subset of genes by choosing the genes with the largest Cox
scores. However, this method is a purely supervised proce-
dure. It does not apply any unsupervised methods (such as
clustering or principal components analysis) to this subset of
genes to identify additional patterns in the data. We will show
that our semi-supervised procedures generally perform
better than this method.
Summary
Our goal is to identify subtypes of cancer that are both
clinically relevant and biologically meaningful. Suppose that
we have n patients, and we measure the expression level of p
genes for each patient. (Note that n   p.) We assume that
there are several different types (classes) of cancer, each of
which responds differently to treatment, and each of which is
distinct at the molecular level. Therefore, given a set of n
patients with different classes of cancer, we wish to train a
classiﬁer that can diagnose which type of cancer a future
patient has, given the expression levels of the patient’s p
genes. We will show that it is possible to identify such
subgroups using the semi-supervised learning techniques
described in the previous paragraph, and that identiﬁcation
of such subgroups can enable us to predict the clinical
outcome of cancer more accurately.
Results
Fully Unsupervised Clustering
As noted in the Introduction, we needed to assign each
patient to a subgroup before we could apply nearest
shrunken centroids. First, we applied an unsupervised 2-
means clustering procedure to the DLBCL data of Rosenwald
et al. (2002). This dataset consisted of measurements on 7399
genes from 240 patients. Of these 240 patients, 160 were used
for training the model and 80 were reserved for validating the
model. A survival time was given for each patient, which
ranged between 0 and 21.8 y.
We compared the survival times of the two subgroups using
a log-rank test. The log-rank test statistic was 0.7, with a
corresponding p-value of 0.416. Thus, conventional clustering
techniques failed to identify subgroups that differed with
respect to their survival times. Subgroups identiﬁed using
hierarchical clustering also did not differ with respect to
survival (data not shown).
Using Clinical Data Alone to Generate Class Labels
We assigned each patient in the training data to either a
‘‘low-risk’’ or ‘‘high-risk’’ subgroup based on their survival
time (see ‘‘Materials and Methods’’ for details.) After applying
nearest shrunken centroids with crossvalidation, we selected a
model that used 249 genes. We then used this model to assign
each patient in the independent test data to the ‘‘low-risk’’ or
‘‘high-risk’’ group. The plots of the two survival curves
associated with the two classes generated by the model are
shown in Figure 2. The p-value of the log-rank test was 0:03.
Supervised Clustering
In order to identify tumor subclasses that were both
biologically meaningful and clinically relevant, we applied a
novel, supervised clustering procedure to the DLBCL data.
We ranked all of the genes based on their univariate Cox
proportional hazards scores, and performed clustering using
only the ‘‘most signiﬁcant’’ genes.
Recall that when we performed 2-means clustering on the
patients in the test data using all 7,399 genes and used a log-
rank test to compare the survival times of the patients in the
two resulting clusters, the result was not signiﬁcant. To test
our new clustering method, we calculated the Cox scores of
all 7,399 genes based on the 160 training observations and
ranked the genes from largest to smallest based on their
absolute Cox scores. We then clustered the 80 test observa-
tions using only the 25 top-scoring genes. This time, the log-
rank statistic comparing the survival times of the two clusters
was highly signiﬁcant ( p ¼ 0:0001). A plot of the two resulting
survival curves is shown in Figure 3. A plot of the survival
curves that we obtained by applying 2-means clustering to all
of the genes is also shown for comparison.
Other Clustering Methods
Both Ben-Dor et al. (2001) and von Heydebreck et al. (2001)
used a subset of the genes to try to cluster a microarray
dataset in a biologically meaningful manner. They observed
that clustering using a subset of the genes can produce better
results than using all of the genes. However, these methods
were still fully unsupervised since they used only the gene
expression data to perform the clustering. They did not use
the clinical data to identify subgroups.
Although these methods do a better job of identifying
biologically meaningful clusters than clustering based on all
of the genes, there is no guarantee that the clusters thus
identiﬁed are associated with the clinical outcome of interest.
Indeed, both Ben-Dor et al. (2001) and von Heydebreck et al.
(2001) applied their procedures to a small DLBCL dataset of
40 patients (Alizadeh et al. 2000). The clusters they identiﬁed
did not (with a few exceptions) differ signiﬁcantly from one
another with respect to survival.
Figure 2. Comparison of the Survival Curves of the ‘‘Low-Risk’’ and
‘‘High-Risk’’ Groups
These were obtained by applying nearest shrunken centroids to the
DLBCL test data. Patients in the training data were assigned to either
the ‘‘low-risk’’ or ‘‘high-risk’’ group depending on whether or not
their survival time was greater than the median survival time of all the
patients.
DOI: 10.1371/journal.pbio.0020108.g002
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Methods to Predict Patient SurvivalWe applied the clustering procedure of von Heydebreck et
al. (2001) to the larger DLBCL dataset of Rosenwald et al.
(2002). Figure 4 shows the survival curves of the two clusters
generated using this method. The survival curves generated
by clustering on the genes with the largest Cox scores are
included for comparison. Note that the two subgroups
identiﬁed using the clustering procedure of von Heydebreck
et al. (2001) do not differ signiﬁcantly with respect to survival.
Survival Diagnosis
We showed that the cancer subgroups identiﬁed using this
supervised clustering method can be used to predict survival
in future patients. The idea is straightforward. First, we
identiﬁed subgroups of patients using supervised clustering.
Then we trained a nearest shrunken centroid classiﬁer to
predict the subgroup to which each patient belonged. Details
are given in ‘‘Material and Methods.’’
We tested this procedure on the DLBCL data. A clustering
based on 343 genes produced the smallest crossvalidation
error rate, so we used a classiﬁer based on this clustering to
assign each of the 80 test patients to one of the two
subgroups. The survival curves of the two predicted sub-
groups are shown in Figure 5; the p-value of the log-rank test
comparing the two survival curves is 0:008.
Supervised Principal Components
We used a form of the principal components of the
expression matrix to predict survival. Principal components
Figure 3. Comparison of the Survival
Curves Resulting from Applying Two Dif-
ferent Clustering Methods to the DLBCL
Data
DOI: 10.1371/journal.pbio.0020108.g003
Figure 4. Comparison of the Survival
Curves Resulting from Applying Two Dif-
ferent Clustering Methods to the DLBCL
Data
DOI: 10.1371/journal.pbio.0020108.g004
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Methods to Predict Patient Survivalanalysis is an unsupervised learning technique that is used to
reduce the dimensionality of a dataset by calculating a series
of ‘‘principal components.’’ The hope is that the ﬁrst few
principal components will summarize a large percentage of
the variability in the entire dataset. See Hastie et al. (2001b)
for a description of principal components analysis.
Unfortunately, principal components analysis suffers from
the same limitations as purely unsupervised clustering. If we
perform principal components analysis using all of the genes
in a dataset, there is no guarantee that the resulting principal
components will be associated with survival. Thus, we
propose a semi-supervised form of principal components
analysis that we call ‘‘supervised principal components.’’
Rather than using all of the genes when we perform principal
components analysis, we use only a subset of the genes that
are correlated with survival.
Using the 160 training observations, we computed the Cox
scores for each gene. We kept the 17 genes with Cox scores of
2:39 or greater. We calculated the principal components of
the training data using only these 17 genes. Then we
approximated the principal components of the test data
using equation (11) (see ‘‘Materials and Methods’’ for details.)
Figure 6 shows that there does appear to be a correlation
between the value of the ﬁrst principal component, ^ v v1, and
patient survival. To conﬁrm this observation, we ﬁt a Cox
proportional hazards model to a linear combination of ^ v v1 and
^ v v2, the estimated ﬁrst and second principal components of
the test data, respectively. (See ‘‘Materials and Methods’’ for a
description of how this linear combination was obtained.)
The resulting sum was a signiﬁcant predictor of survival
(R2 ¼ 0:113, likelihood ratio test statistic = 9.58, 1 d.f.,
p ¼ 0:00197). This predictor is stronger than the discrete
predictor shown in Figure 5 (R2 ¼ 0:08, likelihood ratio test
statistic ¼ 6:7, 1 d.f., p ¼ 0:00966).
A Breast Cancer Example
Thus far, all of our examples have been based on the
DLBCL data of Rosenwald et al. (2002). We now apply our
methodology to a set of breast cancer microarray data. In a
recent study, van’t Veer et al. (2002) built a model to predict
the time to metastasis of breast cancer in patients based on
microarray data from 78 patients. They showed that this
model could be used to predict the times to metastasis of 20
independent test patients. Later, in a separate study, this
same model was applied to a much larger set of 292 patients
(van de Vijver et al. 2002).
Unfortunately, the expression levels of only 70 genes were
available for the 292 patient dataset, making it difﬁcult to test
our methodology. However, we were able to apply our
supervised principal components method. The expression
levels of approximately 25,000 genes were available for the
earlier study (consisting of 78 patients). After applying
crossvalidation, we selected a model consisting of eight genes,
ﬁve of which were included among the 70 genes in the larger
dataset. Thus, we ﬁt a supervised principal components
model using these ﬁve genes and applied it to the dataset of
292 patients.
The results are shown in Table 1. (To compare the
predictive power of the various models, we ﬁt a Cox
proportional hazards model to each predictor and computed
the R2 statistic for each model. R2 measures the percentage of
the variation in survival time that is explained by the model.
Thus, when comparing models, one would prefer the model
with the larger R2 statistic.) We see that our supervised
principal components method produced a stronger predictor
of metastasis than the procedure described in van’t Veer et al.
(2002). Furthermore, our method used only ﬁve genes,
whereas the predictor of van’t Veer et al. (2002) used 70
genes. These results held even though we did not have the
expression data for three genes that we would like to have
included in our model.
(Of the 78 patients used to build the model in the original
study, 61 were included in the larger dataset of 292 patients.
Thus, the values of R2 calculated using all 292 patients are
inﬂated, since part of the dataset used to validate the model
was also used to train the model. We include these results
merely to demonstrate the greater predictive power of our
methodology. Moreover, we repeated these calculations using
only the 234 patients that were not included in the earlier
study to ensure that our results were still valid.)
Figure 5. Survival Curves for Clusters Derived from the DLBCL Data
DOI: 10.1371/journal.pbio.0020108.g005
Figure 6. Plot of Survival Versus the Predictor ^ v v for the DLBCL Data
DOI: 10.1371/journal.pbio.0020108.g006
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Methods to Predict Patient SurvivalComparison With Related Methods in the Literature
We compared each of our proposed methods to several
previously published methods for predicting survival based
on microarray data. In particular, we examined three
previously published procedures: a method based on SVMs
(Li and Luan 2003), a method based on PLS (Nguyen and
Rocke 2002a), and an ad hoc procedure that calculated a ‘‘risk
index’’ for each patient by taking an appropriate linear
combination of a subset of the genes (Beer et al. 2002).
Finally, we considered a naive procedure that split the
training data into two groups by ﬁnding the bipartition that
minimized the p-value of the resulting log-rank statistic. A
brief description of each of these procedures is given in
Protocol S1; for a full description of these procedures, see the
original papers.
We compared these methods on four different datasets
(See Datasets S1-S13). First, we examined the DLBCL dataset
(Rosenwald et al. 2002) that we used in the earlier examples.
Recall that there were 7,399 genes, 160 training patients, and
80 test patients. Second, we considered a breast cancer
dataset (van’t Veer et al. 2002). There were 4,751 genes and 97
patients in this dataset. We partitioned this dataset into a
training set of 44 patients and a test set of 53 patients. Third,
we examined a lung cancer dataset (Beer et al. 2002). There
were 7,129 genes and 86 patients, which we partitioned into a
training set of 43 patients and a test set of 43 patients. Finally,
we considered a dataset of acute myeloid leukemia patients
(Bullinger et al. 2004). It consisted of 6,283 genes and 116
patients. This dataset was partitioned into a training set of 59
patients and a test set of 53 patients. The results are shown in
Table 2.
A Simulation Study
We compared each of the methods we proposed above on
two simulated datasets. (See Data S1-S4.) The ﬁrst simulated
dataset X had 5,000 genes and 100 samples. All expression
values were generated as standard normal random numbers
with a few exceptions. Genes 1–50 in samples 1–50 had a
mean of 1:0. We randomly selected 40% of the samples to
have a mean of 2:0 in genes 51–100, 50% of the samples to
have a mean of 1:0 in genes 101–200, and 70% of the samples
to have a mean of 0:5 in genes 201–300.
We then generated survival times. The survival times of
samples 1–50 were generated as normal random numbers
with a mean of 10:0 and a standard deviation of 2:0, and the
survival times of samples 51–100 were generated as normal
random numbers with a mean of 8:0 and a standard deviation
of 3:0. For each sample, a censoring time was generated as a
normal random number with a mean of 10:0 and a standard
deviation of 3:0. If the censoring time turned out to be less
than the survival time, the observation was considered to be
censored. Finally, we generated another 50003100 matrix of
test data ~ X X, which was generated the same way X was
generated. Survival times for ~ X X were also generated in an
identical manner.
We deﬁned samples 1–50 as belonging to ‘‘tumor type 1’’
and samples 51–100 as belonging to ‘‘tumor type 2.’’ Thus, a
successful subgroup discovery procedure should assign
samples 1–50 to one subgroup, and samples 51–100 to the
other subgroup.
We applied the methods discussed above to identify these
subgroups (and predict survival) for the simulated dataset.
This simulation was repeated ten times. The results are shown
in Table 3. The ﬁrst column of the table shows how many
samples were misclassiﬁed when the dataset was originally
divided into two subgroups. The second column shows the
number of crossvalidation errors that occurred when the
nearest shrunken centroids model was applied to these
putative class labels. The third column shows the number of
incorrectly labeled samples when the optimal nearest
shrunken centroids model was used to assign labels to the
samples in the test data ~ X X. The ﬁnal column is the value of R2
obtained by ﬁtting a Cox proportional hazards model to the
predicted class labels for the test data (or by ﬁtting a Cox
model to ^ c c in the case of methods 4 and 6).
In the ﬁrst simulation, we found that the fully supervised
and the fully unsupervised methods produced much worse
results than the semi-supervised methods. (For each iteration
of the ‘‘median cut’’ method, the crossvalidation error was
minimized when all of the observations were assigned to the
same class. Hence, each such model had no predictive power,
and the value of R2 was zero for each iteration. If we had
chosen a smaller value of the tuning parameter D, the
procedure would have performed better, although not
signiﬁcantly better.) The continuous predictor based on
supervised principal components performed nearly as well
as the methods based on semi-supervised clustering.
Next, we performed a second simulation. The second
simulated dataset X had 1000 genes and 100 samples. All
expression values were generated as Gaussian random
variables with a mean of zero and a variance of 1.5, although
again there were a few exceptions. Genes 1–50 had a mean of
0:5 in samples 1–20, a mean of 0:6 in samples 21–40, a mean
of 0:7 in samples 41–60, a mean of 0:8 in samples 61–80, and a
mean of 0:9 in samples 81–100. And again, we randomly
selected 40% of the samples to have a mean of 2:0 in genes
51–100, 50% of the samples to have a mean of 1:0 in genes
101–200, and 70% of the samples to have a mean of 0:5i n
genes 201–300. To generate the survival time of each
‘‘patient,’’ we took the sum of the expression levels of the
ﬁrst 50 genes and added a Gaussian noise term with variance
0:01. There was no censoring mechanism for the second
simulation. We also generated another 1000 3 100 matrix of
test data using an analogous procedure.
Under this model, there are actually ﬁve ‘‘tumor sub-
groups.’’ However, we still used 2-means clustering on this
simulated dataset in order to evaluate the performance of our
Table 1. Supervised Principal Components Applied to Breast
Cancer Data
Supervised Principal
Components
Method of
van’t Veer et al. (2002)
n = 292 0.155 (3.12 3 10
 5) 0.072 (0.00934)
n = 234 0.114 (0.00328) 0.098 (0.0105)
Comparison of the values of the R
2 statistic of the Cox proportional hazards model
(and the p-value of the associated log-rank statistic) obtained by fitting the times
to metastasis to our supervised principal components method and the discrete
predictor described in van’t Veer et al. (2002).
DOI: 10.1371/journal.pbio.0020108.t001
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Methods to Predict Patient Survivalmethods when the number of clusters is chosen incorrectly.
Thus, in this simulation, it does not make sense to talk about
the number of ‘‘misclassiﬁcation errors;’’ we can only
compare the methods on the basis of their predictive ability.
We applied the six different methods to this new simulated
dataset and repeated this simulation ten times; the results are
shown in Table 4. The supervised principal component
method is the clear winner in the second simulation study.
The semi-supervised methods performed poorly because
there were a large number of subgroups and there was a
considerable overlap between subgroups. This example
demonstrates that the supervised principal component
method performs well regardless of the number of tumor
subclasses and that it seems to perform especially well when
survival is an additive function of the expression level of
certain genes.
Discussion
One important goal of microarray research is to develop
more powerful diagnostic tools for cancer and other diseases.
Consider a hypothetical cancer that has two subtypes. One
subtype is known to spread much more rapidly than the other
subtype, and hence must be treated much more aggressively.
We would like to be able to diagnose which type of cancer
patients have and give them the appropriate treatment.
If it is known that two such subtypes of a certain cancer
exist, and if we have a training set where it is known which
patients have which subtype, then we can use nearest
shrunken centroids or other classiﬁcation methods to build
a model to diagnose this cancer in future patients. However,
in many cases, we do not know how many subtypes are
present, nor do we know which patients belong to which
Table 2. Comparison of the Different Methods on Four Datasets
Method DLBCL Data Breast Cancer Data Lung Cancer Data AML Data
R
2 p-value R
2 p-value R
2 p-value R
2 p-value
(1) Median Cut 0.054 0.0297 0.134 0.00423 0.153 0.00162 0.068 0.0487
(2) Clustering-Cox 0.080 0.00755 0.207 0.000127 0.074 0.0499 0.080 0.0309
(3) Supervised PC 0.113 0.00124 0.267 2.06 3 10
 5 0.361 1.47 3 10
 7 0.161 0.00136
(4) Clustering-PLS 0.114 0.00087 0.143 0.00123 0.106 0.00354 0.064 0.050
(5) y ^ 0.292 1.21 3 10
 8 0.224 0.000436 0.171 0.00496 0.029 0.201
(6) 2-Means 0.014 0.286 NA NA 0.021 0.33 0.001 0.803
(7) Best p-value 0.013 0.273 0.113 0.00371 0 0.946 0.034 0.141
(8) SVM (cont) 0.034 0.0875 0.155 0.0025 0.026 0.298 0.024 0.247
(9) SVM (disc) 0.052 0.033 0.179 0.000345 0.041 0.195 0.062 0.0646
(10) PLS Reg. (cont) 0.047 0.048 0.181 0.000322 0.176 0.0043 0.069 0.0489
(11) PLS Reg. (disc) 0.032 0.101 0.211 8.2 3 10
 5 0.098 0.0194 0.011 0.438
(12) Beer et al. (2002) 0.007 0.441 0.155 0.00238 0.091 0.0419 0.018 0.311
Comparison of the different methods applied to the DLBCL data of Rosenwald et al. (2002), the breast cancer data of van’t Veer et al. (2002), the lung cancer data of Beer et al
(2002), and the acute myeloid leukemia (AML) data of Bullinger et al. (2004). The methods are (1) assigning samples to a ‘‘low-risk’’ or ‘‘high-risk’’ group based on their
median survival time; (2) using 2-means clustering based on the genes with the largest Cox scores; (3) using the supervised principal components method; (4) using 2-means
clustering based on the genes with the largest PLS-corrected Cox scores; (5) using the continuous predictor ^ c c ; (6) using 2-means clustering to identify two subgroups; (7)
partitioning the training data into ‘‘low-risk’’ and ‘‘high-risk’’ subgroups by choosing the split that minimizes the p-value of the log-rank test when applied to the two
resulting groups; (8) using SVMs, similar to the method of Li and Luan (2003); (9) using a discretized version of (8); (10) Using partial least squares regression, similar to the
method of Nguyen and Rocke (2002a); (11) using a discretized version of (11); (12) using the method of Beer et al. (2002).
DOI: 10.1371/journal.pbio.0020108.t002
Table 3. Comparison of the Different Methods on Our Simulated Data
Method Initial Cluster Errors Crossvalidation Errors Test Errors R
2
(1) Median cut 35.7 (6.15) 50.0 (0.0) 50.0 (0.0) 0.0 (0.0)
(2) 2-means 46.5 (0.93) 46.6 (0.90) 46.2 (1.44) 0.0073 (0.0019)
(3) Clustering-Cox 23.4 (3.49) 16.7 (6.16) 16.6 (6.49) 0.11 (0.025)
(4) Supervised PC NA NA NA 0.077 (0.023)
(5) Clustering-PLS 17.1 (6.82) 15.4 (7.00) 13.8 (6.72) 0.11 (0.030)
(6) y ^ NA NA NA 0.013 (0.0034)
The methods are (1) assigning samples to a ‘‘low-risk’’ or ‘‘high-risk’’ group based on their median survival time; (2) using 2-means clustering to identify two subgroups; (3)
using 2-means clustering based on the genes with the largest Cox scores; (4) using the supervised principal components method; (5) using 2-means clustering based on the
genes with the largest PLS-corrected Cox scores; (6) using the continuous predictor ^ c c. Each entry in the table represents the mean over 10 simulations; the standard error is
given in parentheses.
DOI: 10.1371/journal.pbio.0020108.t003
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identify such subgroups.
Unsupervised methods, such as hierarchical clustering, are
popular techniques for identifying such subgroups. However,
there is no guarantee that subgroups discovered using
unsupervised methods will have clinical signiﬁcance.
An alternative is to generate class labels using clinical data.
The simplicity of the approach of dividing the patients into
two subclasses based on their survival time is attractive, and
there is evidence that this procedure can successfully predict
survival. Indeed, this procedure produced a signiﬁcant
predictor of survival in four different datasets, suggesting
that this approach has some utility. However, as noted in the
Introduction, subgroups identiﬁed in this manner may not be
biologically meaningful. When we applied this model to the
DLBCL data described earlier, the misclassiﬁcation error rate
for the shrunken centroids model was very high (around
40%), so a diagnosis based on this procedure is likely to be
inaccurate.
Supervised clustering methods can overcome these prob-
lems. We have seen that if we selected signiﬁcant genes prior
to clustering the data, we could identify clusters that were
clinically relevant. We have also seen how knowledge of these
clusters could be used to diagnose future patients.
This supervised clustering methodology is a useful prog-
nostic tool. It is also easy to interpret. However, it has certain
shortcomings as well. Recall our conceptual model shown in
Figure 1. Patients with tumor type 2 live longer than patients
with tumor type 1 on average, but there is still signiﬁcant
variability within each tumor type. Even if we can diagnose a
patient with the correct tumor type 100% of the time, the
prognosis of the patient may be inaccurate if the variability in
survival time within each tumor type is large. Thus, it would
be desirable to ﬁnd a continuous predictor of survival that
accounts for this within-group variability.
One possible such predictor is our supervised principal
components procedure. This procedure used the principal
components of a subset of the expression matrix X as a
predictor of patient survival. The chosen subset contained
the genes with the largest Cox scores. This method could also
be used to detect cancer subtypes, since the principal
components will presumably capture the variation that exists
between subtypes. It is also capable of identifying variation
within these subtypes, which, as discussed above, cannot be
identiﬁed using supervised clustering. We showed that this
procedure could produce a stronger predictor of survival
than the discrete predictor based on supervised clustering.
We compared our methods to several previously published
methods for predicting survival based on microarray data. In
general, our methods performed signiﬁcantly better than
these existing methods. In particular, our supervised princi-
pal components method gave the best results on three of the
four datasets. (It performed slightly worse than our ^ c c method
on the DLBCL data, but it still outperformed almost all of the
other methods.) Furthermore, each of our proposed methods
was a signiﬁcant predictor of survival (at p ¼ 0:05) for all four
datasets, which was not true for any of the other methods.
Finally, if we consider only discrete predictors of survival, our
semi-supervised clustering methods performed better than
the other models on at least three of the four datasets.
Another important advantage of our methods is that they
select a subset of the genes to use as predictors. The methods
of Nguyen and Rocke (2002a) and Li and Luan (2003), by
contrast, require the use of all (or a large number) of the
genes. If we can identify a small subset of genes that predict
the survival of cancer patients, it may be possible to develop a
diagnostic test using immunostaining or reverse transcriptase
PCR. However, such a test would not be feasible if hundreds
or thousands of genes were necessary to make the diagnosis.
Throughout this study, we have used survival data to help
us identify genes of interest. However, other clinical variables
could also be used, such as the stage of the tumor, or whether
or not it has metastasized. Rather than ranking genes based
on their Cox scores, one would use a different metric to
measure the association between a given gene and the clinical
variable of interest. For example, suppose we wished to
identify a subgroup of cancer that was associated with a high
risk of metastasis. For each gene, we could compute a t-
statistic comparing the expression levels in the patients
whose cancer metastasized to those in the patients with no
metastasis. Tusher et al. (2001) described methods for
generating such ‘‘signiﬁcant gene lists’’ for a variety of
possible clinical variables. Many of these methods are
implemented in the signiﬁcance analysis of microarrays
software package (Chu et al. 2002).
Information about the risk of metastasis (and death) for a
given patient is essential to treat cancer successfully. If the
risk of metastasis is high, the cancer must be treated
aggressively; if the risk is low, milder forms of treatment
can be used. Using DNA microarrays, researchers have
successfully identiﬁed subtypes of cancer that can be used
to assess a patient’s risk proﬁle. Our results show that semi-
supervised learning methods can identify these subtypes of
cancer and predict patient survival better than existing
methods. Thus, we believe they can be a powerful tool for
diagnosing and treating cancer and other genetic diseases.
Materials and Methods
Overview of nearest shrunken centroids. The nearest shrunken
centroids procedure calculates the mean expression of each gene
Table 4. Comparison of the Different Methods on Our Simulated
Data
Method R
2
(1) Median Cut 0.055 (0.011)
(2) 2-means 0.017 (0.0049)
(3) Clustering-Cox 0.035 (0.012)
(4) Supervised PC 0.33 (0.060)
(5) Clustering-PLS 0.036 (0.014)
(6) ^ c c 0.068 (0.014)
The methods are (1) assigning samples to a ‘‘low-risk’’ or ‘‘high-risk’’ group based
on their median survival time; (2) using 2-means clustering to identify two
subgroups; (3) using 2-means clustering based on the genes with the largest Cox
scores; (4) using the supervised principal components method; (5) using 2-means
clustering based on the genes with the largest PLS-corrected Cox scores; (6) using
the continuous predictor ^ c c. Each entry in the table represents the mean over 10
simulations; the standard error is given in parentheses.
DOI: 10.1371/journal.pbio.0020108.t004
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mean for that gene by a ﬁxed quantity, D.D i a g o n a ll i n e a r
discriminant analysis (LDA) is then applied to the genes that survive
the thresholding. Details are given in Tibshirani et al. (2002). It has
successfully classiﬁed tumors based on gene expression data in
previous studies. In one experiment, there were a total of 88 patients,
each of which had one of four different types of small round blue cell
tumors . Nearest shrunken centroids classiﬁed 63 training samples
and 25 test samples without a single misclassiﬁcation error
(Tibshirani et al. 2002).
Generation of ‘‘median cut’’ class labels. We created two classes by
cutting the survival times at the median survival time (2.8 y). Any
patient who lived longer than 2.8 y was considered to be a ‘‘low-risk’’
patient, and any patient that lived less than 2.8 y was considered to be
a ‘‘high-risk’’ patient. In this manner, we assigned a class label to each
observation in the training data.
Unfortunately, many of the patients’ survival times were censored,
meaning that the individual left the study before the study was
completed. When this occurs, we do not know how long the patient
survived; we only know how long the patient remained in the study
prior to being lost to follow-up.
If an observation is censored, we may not know to which class it
belongs. For example, suppose that the median survival time is 2.8 y,
but that a patient left the study after 1.7 y. If the patient died in the
interval between 1.7 y and 2.8 y, then the patient should be assigned
to the ‘‘high-risk’’ group. Otherwise, the patient should be assigned to
the ‘‘low-risk’’ group. However, there is no way to determine which
possibility is correct.
Based on the Kaplan-Meier survival curve for all the patients, we
can estimate the probability that a censored case survives a speciﬁed
length of time (Cox and Oakes 1984; Therneau and Grambsch 2000).
For example, suppose that the median survival time is 50 months and
a patient left the study after 20 months. Let T denote the survival
time of this patient. Then, using the Kaplan-Meier curve, we can
estimate PðT.50Þ and PðT.20Þ. Then we can estimate
PðT.50jT.20Þ as follows:
PðT.50jT.20Þ¼
PðT.50Þ
PðT.20Þ
; ð1Þ
and, of course,
PðT   50jT.20Þ¼1   PðT.50jT.20Þ: ð2Þ
In this manner, we can estimate the probability that each censored
observation belongs to the ‘‘low-risk’’ and ‘‘high-risk’’ classes,
respectively.
However, it is still unclear how we would train our classiﬁer based
on this information. Nearest shrunken centroids is a modiﬁed version
of LDA. It is described in detail in Hastie et al. (2001b). Like most
classiﬁcation techniques, LDA assumes that the class labels of the
training observations are known with complete certainty. The version
of LDA described in Hastie et al. (2001b) and most other books
cannot handle probabilistic class labels, where there is a certain
probability that a training observation belongs to one class, and a
certain probability that it belongs to a different class. We will now
describe a simple modiﬁcation of LDA that can be trained based on
this type of data. It is similar to a technique described in McLachlan
(1992) for training an LDA classiﬁer when some of the training
observations are missing.
Let fxig
nþm
i¼1 denote the set of input variables, and let fyig
nþm
i¼1
represent the corresponding response variables. Also, let g represent
the number of discrete classes to which the yis may belong. (If we are
dividing the training data into ‘‘low-risk’’ and ‘‘high-risk’’ patients,
then g ¼ 2.) When we perform LDA when all of the yis are known, the
problem is to ﬁt the mixture model
fXðx;UÞ¼
X g
i¼1
pifiðx;hiÞ: ð3Þ
(Generally, each fi is a Gaussian density function, and the his
correspond to the mean of the observations in each class. The pis
correspond to ‘‘prior’’ probabilities that an observation belongs to
class i.) In this case, we must ﬁt this model on the basis of the classiﬁed
(uncensored) training data, which we denote by t, and the unclassiﬁed
(censored) feature vectors xj ( j ¼ n þ 1; ...;n þ m), which we denote
by tu. (Also, note that U ¼ð p9;h9Þ9 denotes the vector of all unknown
parameters.)
We deﬁne the latent variables zij to be equal to one if the jth
observation belongs to the ith class, and zero otherwise. Then the
complete-data log likelihood is
logLCðUÞ¼
X g
i¼1
X nþm
j¼1
zijlogfiðxj;hiÞþ
X g
i¼1
X nþm
j¼1
zijlogpi: ð4Þ
The EM algorithm is applied to this model by treating
zj(j ¼ n þ 1; ...;n þ m) as missing data. It turns out to be very simple
in the case of LDA. The E-step is effected here simply by replacing
each unobserved indicator variable zij by its expectation conditional
on xj. That is, zij is replaced by the estimate of the posterior
probability that the jth entity with feature vector xj belongs to
Gi(i ¼ 1; ...;G;j ¼ n þ 1; ...;n þ m) (McLachlan 1992). We take the
initial estimates of zij to be the earlier estimate that the ith censored
observation belongs to class j based on the Kaplan-Meier curve.
The estimates of pi and li in the M-step are equally simple:
^ p p
ðkþ1Þ
i ¼f ni þ
X nþm
j¼nþ1
siðxj;UðkÞÞg=ðn þ mÞð 5Þ
and
^ l l
ðkþ1Þ
i ¼f
X n
j¼1
zijxj þ
X nþm
j¼nþ1
siðxj;UðkÞÞxjg=MiðUðiÞÞ; ð6Þ
where
MiðUðkÞÞ¼f ni þ
X nþm
j¼nþ1
siðxj;UðkÞÞgði ¼ 1; ...;gÞ: ð7Þ
In these expressions, siðx;UÞ is the posterior probability that the jth
entity with feature vector xj belongs to Gi, or, in other words,
siðx;UÞ¼
piexpf ð x   liÞ
2=2g
X g
h¼1
phexpf ð x   lhÞ
2=2g
: ð8Þ
We continue these imputations until the algorithm converges. In
practice, one imputation seems to be sufﬁcient for most problems,
since each imputation is computationally intensive, and additional
imputations did not seem to change the results signiﬁcantly.
Diagnosing patient survival via supervised clustering. We calcu-
lated the Cox scores of each gene based on the 160 training
observations, and obtained a list of the most signiﬁcant genes. Then
we performed 2-means clustering on these 160 observations using the
genes with the largest absolute Cox scores and obtained two
subgroups. We repeated this procedure multiple times with different
numbers of genes. For each such clustering, we trained a nearest
shrunken centroid classiﬁer to assign future patients to one subgroup
or the other and examined the crossvalidation error rate.
The problem of choosing the number of genes on which to
perform the clustering is more complicated than it appears. The
obvious way to choose the optimal number of genes on which to
cluster is to simply minimize the crossvalidation error rate of the
nearest shrunken centroids model based on the clustering. This works
up to a certain point. It is possible that the clustering procedure will
identify a cluster that is unrelated to survival. (Since we are clustering
on the genes with the highest Cox scores, this is unlikely to occur.
However, it is still possible, especially if the number of genes on
which we are clustering is large.) Thus, we needed to build a safeguard
against this possibility into ourp r o c e d u r e .A f t e rp e r f o r m i n g
clustering based on a given set of high-scoring genes, we performed
a log-rank test to determine if the resulting clusters differed with
respect to survival. If they did not, the clustering was discarded
without further analysis. An outline of the procedure follows: (1)
Choose a set G of possible values of C. (2) Let pmin ¼ 1 and emin ¼ 1.
(3) For each C in G, do the following: (4) Perform k-means clustering
using only those genes with absolute Cox scores greater than C. (5)
Perform a log-rank test to test the hypothesis that the k clusters have
different survival rates. Call the p-value of this test p. (6) If p   pmin,
then return to step 3. (7) Fit a nearest shrunken centroids model
based on the clusters obtained in step 3. Calculate the minimum
crossvalidation error rate across all values of the shrinkage
parameter, and call it e. (8) If e,emin, then let Cbest ¼ C, and return
to step 3. Otherwise return to step 3 without changing the value of
Cbest. The optimal value of C is taken to be the value of Cbest when this
procedure terminates.
Several comments about this procedure are in order. First, note
that we did not recalculate the Cox scores at each fold of the
crossvalidation procedure. We calculated them only once, using all of
the patients in the dataset. There are several reasons for doing this.
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expensive computationally. Moreover, we found that the Cox score of
a given gene varied depending on the number of patients (and which
patients) we included in the model. Thus, if a given value of C
produced a low crossvalidation error rate, there was no guarantee
that a model based on the full dataset using this value of C would
produce good results, since the model based on the full dataset may
use a different list of genes. Other studies have found that using the
entire dataset to produce a ‘‘signiﬁcant gene list’’ prior to performing
crossvalidation can produce more accurate predictions (van’t Veer et
al. 2002).
Also, the set G was left unspeciﬁed in the procedure. The choice of
which (and how many) possible values of C to include in G depends on
the problem at hand, as well as the computational power available. As
a default, we recommend trying 100 evenly spaced values of C
between the 90th percentile of the Cox scores and the maximum of
the Cox scores. However, the optimal Cbest varies greatly from dataset
to dataset, so we recommend trying several different forms of G if
adequate computing power exists.
Furthermore, note that when we calculated the p-value of the log-
rank test after performing the original clustering, we insisted not only
that the p-value be signiﬁcant, but also that it be lower than the best
p-value obtained thus far. The reasons for this are twofold. First,
experience suggests that if a given set of genes produces a good
clustering on the training data (‘‘good’’ deﬁned as having a low p-
value from a log-rank test), then it is likely to produce a good
clustering on the test data. (We offer no theoretical or biological
justiﬁcation for this statement; it simply represents our experience.
However, we have observed this result a sufﬁcient number of times to
convince us that it is not coincidental.) Moreover, this speeds up the
algorithm substantially. Calculating the nearest shrunken centroids
crossvalidation error rate for a given clustering is the slowest part of
the procedure; the time required to perform the clustering and
calculate the log-rank statistic is insigniﬁcant in comparison. Thus, by
only considering clusterings which produce a log-rank statistic with a
small p-value, we allow the set G to be much larger than would be
feasible otherwise.
Finally, the number of clusters k was unspeciﬁed in the procedure.
We have experimented with some algorithms to choose the value of k
automatically, but without success. If possible, we recommend that
the value of k be chosen based on prior biological knowledge.
(Perhaps one could ﬁrst perform hierarchical clustering, examine a
dendogram of the data, and visually search for major subgroups.) If
this is not possible, we recommend trying several different small
values of k and choosing the one that gives the best results. (Our
experience suggests that choosing k ¼ 2 will give good results for
almost all datasets.)
Supervised principal components. As above, let X be the p3n
matrix of expression values, for p genes and n patients. Let xij denote
the expression level of the ith gene in the jth patient. Assume that
each patient has one of two possible underlying tumor types. Without
loss of generality, assume that patients 1; ...;m have tumor type 1,
and that patients m þ 1; ...;n have tumor type 2. Then assume that
the genetic proﬁles of the two tumor types are distinct from one
another, which is equivalent to assuming that the joint distribution of
ðx1j; ...;xpjÞ is different for 1   j   m than it is for m þ 1   j   n.
Thus, if we choose constants faig
p
i¼1, the distribution of
Pp
j¼1 ajxij will
be different for 1   j   m than it is for m þ 1   j   n. (Obviously, this
is not true for all values of faig
p
i¼1. For example, if we let ai ¼ 0 for all
i, then this statement will not hold. However, it will generally be true
unless we deliberately choose a pathological set faig
p
i¼1.)
In particular, consider the singular value decomposition of X:
X ¼ UDVT; ð9Þ
where U is a p3n orthogonal matrix, D is an n3n diagonal matrix,
and V is an n3n orthogonal matrix (Horn and Johnson 1985). Then
the matrix V can be written as
V ¼ XTUD 1: ð10Þ
In other words, for a given column of V, each row of V is a linear
combination of the expression values in the corresponding column of
X. Thus, by the argument in the preceding paragraph, rows 1 through
m should have a different distribution than rows m þ 1 through n.
Hence, we propose that the ﬁrst few columns of V be used as
continuous predictors of survival for each patient. Formally,
^ V V ¼ XTUD 1: ð11Þ
Moreover, suppose that we have an independent test set ~ X X. Then let
^ V V ¼ ~ X X
T
UD 1; ð12Þ
where U and D are the same as in equation (11) (i.e., derived from the
singular value decomposition of the training data). In this case, the
ﬁrst few columns of ^ V V can be used to estimate survival for the
patients in the independent test set.
The reason for choosing the ﬁrst few columns of V is because the
matrix U was chosen so that XTu1 has the largest sample variance
amongst all normalized linear combinations of the rows of X (Hastie
et al. 2001b). (Here, u1 represents the ﬁrst column of U.) Hence,
assuming that variation in gene expression accounts for variation in
survival, we would expect that XTu1 captures a large percentage of
the variation in survival. (Indeed, in some simple models, it can be
proven that equation [11] is the best possible predictor of survival; see
Protocol S1.)
In theory, we could calculate V using the entire dataset X, and the
rows of V would have different distributions depending on the tumor
type of the corresponding patient. In practice, however, many of the
genes in X are unrelated to survival, and if we use the entire dataset X
to compute V, the quality of the resulting predictor is poor. We can
overcome this difﬁculty by using only the genes with the largest Cox
scores. Formally, we construct a matrix X9 consisting of only those
genes whose Cox scores are greater than some threshold C, and take
the singular value decomposition of X9.
To choose the optimal value of C, we employ the following
procedure: (1) Choose a set G of possible values of C. (2) For each C in
G, split the training data into k random partitions (i.e., perform k-fold
crossvalidations). For most problems (and for the rest of this
discussion), we can let k ¼ 10. (3) For each crossvalidation fold, take
a singular value decomposition of X, leaving out one of the 10
partitions for validation purposes. Use only those genes with absolute
Cox scores greater than C. (4) Calculate ^ v v for the 10% of the data that
was withheld, as described above. (5) Fit a Cox proportional hazards
model to ^ v v, and calculate the chi-square statistic for the log-rank test
associated with this model. Denote the chi-square statistic for the ith
crossvalidation fold by wi. (6) Average the wis over the 10 cross-
validation folds. Call this average wC. (7) If wC is greater than the value
of wC , then let C  ¼ C and wC  ¼ wC. (8) Return to step 2. The set G is
left unspeciﬁed in the procedure. As a default, we recommend trying
30 evenly spaced values of C between the 90th percentile of the Cox
scores and the maximum of the Cox scores, although this
recommendation is somewhat arbitrary.
In some cases, we can improve the predictive power of our model
by taking a linear combination of several columns of V (rather than
simply taking the ﬁrst column of V). Suppose we wish to ﬁnd a
predictor based on the ﬁrst k columns of V. We can perform the
following procedure: (1) Let X denote the training data. Take the
singular value decomposition of X ¼ UDVT as described above (after
selecting an appropriate subset of the genes). (2) Fit a Cox
proportional hazards model using the ﬁrst k columns of V as
predictors. (3) Calculate the matrix ^ V V for the test data using equation
(12) above. (4) Take a linear combination of the ﬁrst k columns of ^ V V
using the Cox regression coefﬁcients obtained in step 2. Use the
resulting sum as a continuous predictor of survival.
Software and computational details. All computations in this study
were performed using the R statistical package, which is available on
the Internet at http://cran.r-project.org/. R source code for the
procedures described in this paper are available from the authors
upon request (see also Data S1–Data S4). These methods will also be
implemented in a future version of the PAM microarray analysis
package (Tibshirani et al. 2003). (The ‘‘median cut’’ method has been
implemented in version 1.20, which is now available.)
Supporting Information
Data S1. Documentation of Our R Functions
This ﬁle contains a brief description of the functions contained in the
semi-super.R ﬁle.
Found at DOI: 10.1371/journal.pbio.0020108.sd001 (1 KB TXT).
Data S2. R Source Code
This ﬁle contains R functions for implementing the procedures we
have described in our study.
Found at DOI: 10.1371/journal.pbio.0020108.sd002 (6 KB TXT).
Data S3. Source Code for Simulation Study 1
This ﬁle contains the R source code that we used to perform the ﬁrst
simulation study in our paper.
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Data S4. Source Code for Simulation Study 2
This ﬁle contains the R source code that we used to perform the
second simulation study in our paper.
Found at DOI: 10.1371/journal.pbio.0020108.sd004 (39 KB TXT).
Dataset S1. Breast Cancer Expression Data: van’t Veer et al. (2002)
Study
The gene expression data for the breast cancer study of van’t Veer et
al. (2002). We include only the expression levels of 4,751 genes
identiﬁed in the study whose expression varied
Found at DOI: 10.1371/journal.pbio.0020108.sd005 (2.9 MB CSV).
Dataset S2. Breast Cancer Gene Names: van’t Veer et al. (2002) Study
The names of each of the 4,751 genes in the study of van’t Veer et al.
(2002).
Found at DOI: 10.1371/journal.pbio.0020108.sd006 (74 KB CSV).
Dataset S3. Breast Cancer Survival Data: van’t Veer et al. (2002) Study
The clinical data for the study of van’t Veer et al. (2002). The ﬁrst
column represents the time until metastasis (or the time until the
patient left the study); the second column is 1 if the tumor
metastasized and 0 if it did not.
Found at DOI: 10.1371/journal.pbio.0020108.sd007 (1 KB CSV).
Dataset S4. Breast Cancer Expression Data: van de Vijver et al. (2002)
Study
The gene expression data for the 70 genes in the breast cancer study
of van de Vijver et al. (2002).
Found at DOI: 10.1371/journal.pbio.0020108.sd008 (141 KB CSV).
Dataset S5. Breast Cancer Gene Names: van de Vijver et al. (2002)
Study
The names of the 70 genes in the study of van de Vijver et al. (2002).
Found at DOI: 10.1371/journal.pbio.0020108.sd009 (1 KB CSV).
Dataset S6. Repeated Breast Cancer Samples
A single column that is 1 if the patient was included in the earlier
study (that of van’t Veer et al. [2002]), and 0 if the patient was not
included in the earlier study.
Found at DOI: 10.1371/journal.pbio.0020108.sd010 (1 KB CSV).
Dataset S7. Breast Cancer Survival Data: van de Vijver et al. (2002)
Study
The clinical data for the study of van de Vijver et al. (2002). The
format is the same as the format of the earlier ﬁle of clinical data.
Found at DOI: 10.1371/journal.pbio.0020108.sd011 (5 KB CSV).
Dataset S8. DLBCL Expression Data
The gene expression data for the DLBCL study of Rosenwald et al.
(2002).
Found at DOI: 10.1371/journal.pbio.0020108.sd012 (24.38 MB CSV).
Dataset S9. DLBCL Survival Data
The clinical data for the study of Rosenwald et al. (2002). The format
is the same as the format of the clinical data above.
Found at DOI: 10.1371/journal.pbio.0020108.sd013 (2 KB CSV).
Dataset S10. Lung Cancer Gene Expression Data
This is the gene expression data for the lung cancer dataset of Beer et
al. (2002).
Found at DOI: 10.1371/journal.pbio.0020108.sd014 (5.39 MB TXT).
Dataset S11. Lung Cancer Survival Data
This is the clinical data for the lung cancer dataset of Beer et al.
(2002). The format is the same as in the clinical data above.
Found at DOI: 10.1371/journal.pbio.0020108.sd015 (1 KB TXT).
Dataset S12. AML Gene Expression Data
This is the gene expression data for the AML dataset of Bullinger et
al. (2004).
Found at DOI: 10.1371/journal.pbio.0020108.sd016 (9.96 MB TXT).
Dataset S13. AML Survival Data
This is the clinical data for the AML dataset of Bullinger et al. (2004).
It has the same format as the clinical data above.
Found at DOI: 10.1371/journal.pbio.0020108.sd017 (1 KB TXT).
Figure S1. Results of Using PLS-Derived Cox Scores in the Supervised
Clustering Procedure
Found at DOI: 10.1371/journal.pbio.0020108.sg001 (6 KB PDF).
Figure S2. Plot of Survival Versus the Least Squares Estimate of ~ b b for
the DLBCL Data
Found at DOI: 10.1371/journal.pbio.0020108.sg002 (11 KB PDF).
Figure S3. Plot of Survival Versus the Least Squares Estimate of ~ c c for
the DLBCL Data
Found at DOI: 10.1371/journal.pbio.0020108.sg003 (11 KB PDF).
Protocol S1. Additional Models and Methods
Found at DOI: 10.1371/journal.pbio.0020108.sd018 (28 KB TEX).
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